scholarly journals Desensitization in delayed drug hypersensitivity reactions - an EAACI position paper of the Drug Allergy Interest Group

Allergy ◽  
2013 ◽  
Vol 68 (7) ◽  
pp. 844-852 ◽  
Author(s):  
K. Scherer ◽  
K. Brockow ◽  
W. Aberer ◽  
J. H. C. Gooi ◽  
P. Demoly ◽  
...  
Keyword(s):  
Interest Group ◽  
Drug Allergy ◽  
Drug Hypersensitivity ◽  
Position Paper ◽  
Hypersensitivity Reactions ◽  
Drug Hypersensitivity Reactions

In vitrotests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper

Allergy ◽  
2016 ◽  
Vol 71 (8) ◽  
pp. 1103-1134 ◽  
Author(s):  
C. Mayorga ◽  
G. Celik ◽  
P. Rouzaire ◽  
P. Whitaker ◽  
P. Bonadonna ◽  
...  
Keyword(s):  
Interest Group ◽  
Drug Allergy ◽  
Drug Hypersensitivity ◽  
Position Paper ◽  
Hypersensitivity Reactions ◽  
Group Position ◽  
Drug Hypersensitivity Reactions

scholarly journals Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Allergy ◽  
2020 ◽  
Vol 75 (11) ◽  
pp. 2775-2793 ◽  
Author(s):  
Aslı Gelincik ◽  
Knut Brockow ◽  
Gülfem E. Çelik ◽  
Inmaculada Doña ◽  
Cristobalina Mayorga ◽  
...  
Keyword(s):  
Drug Hypersensitivity ◽  
Position Paper ◽  
Hypersensitivity Reactions ◽  
Diagnosis And Management ◽  
Drug Hypersensitivity Reactions

scholarly journals Evaluation of the Drug Hypersensitivity Reactions Prevalence in Hospitalized Children in Sari City from 2014 to 2018: An Original Research

2021 ◽  
Vol 9 (3) ◽  
pp. 229-238
Author(s):  
Hamidreza Houshmand ◽  
◽  
Mohammad Reza Shiran ◽  
Javad Ghaffari ◽  
Mahdi Abounoori ◽  
...  
Keyword(s):  
Drug Reaction ◽  
Urban Areas ◽  
Drug Allergy ◽  
Drug Hypersensitivity ◽  
Original Research ◽  
Hospitalized Children ◽  
Hypersensitivity Reactions ◽  
The North ◽  
Drug Hypersensitivity Reactions ◽  
North Of Iran

Background: Drug allergy is a subtype of Adverse Drug Reaction (ADR) mediated by the immunologic system. Extreme drug allergy is poorly known in children that contribute to hospitalization in our region. Objectives: This research aimed to study major drug hypersensitivity reactions in the north of Iran among the hospitalized children. Methods: This cross-sectional study was conducted at Bou Ali Sina Hospital in the north of Iran. We analyzed the medical files of 140 children admitted to the hospital with drug allergies from 2014 to 2018. The inclusion criteria were based on the DRESS (drug reaction with eosinophilia and systemic symptoms) scoring system, and those who scored more than four were enrolled. Patients with incomplete medical charts were excluded. The sampling methodology was based on the consecutive census method. Results: In the current study, 62 patients were females (44.29%), and 78 were males (55.71%). Ninety-six cases (68.57%) were children under five, and 44 cases (31.43%) were over five years old. Most ADRs were seen in patients from urban areas (58.57%) than in rural areas (41.43%). In 116 children (82.6%), maculopapular rashes were seen. Phenobarbital and cefalexin had the highest levels of drug reactions, including 85 persons (55.19%) and 18 persons (11.69%), respectively. Pruritus, fever, and scaling were the most common symptoms observed in the patients. The most commonly used treatment was antihistamines. Conclusions: The most causative medication inducing ADR was phenobarbital. The maculopapular rash was the most common skin manifestation, and there were no relationships between sex, age, medication type, and type of hypersensitivity reactions.

scholarly journals Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper

Allergy ◽  
2016 ◽  
Vol 71 (11) ◽  
pp. 1533-1539 ◽  
Author(s):  
K. Brockow ◽  
W. Aberer ◽  
M. Atanaskovic-Markovic ◽  
S. Bavbek ◽  
A. Bircher ◽  
...  
Keyword(s):  
Interest Group ◽  
Drug Allergy ◽  
Drug Hypersensitivity ◽  
Position Paper ◽  
Group Position

scholarly journals Hypersensitivity Reactions To Chemotherapy: an EAACI Position Paper

2021 ◽  
Author(s):  
Mauro Pagani ◽  
Sevim Bavbek ◽  
Emilio Alvarez-Cuesta ◽  
patrizia Bonadonna ◽  
Josefina Cernadas ◽  
...  
Keyword(s):  
Drug Allergy ◽  
Task Force ◽  
Drug Hypersensitivity ◽  
The United States ◽  
Position Paper ◽  
Skin Tests ◽  
In Vitro Tests ◽  
Hypersensitivity Reactions ◽  
Chemotherapeutic Drugs ◽  
Cancer Disease

Chemotherapeutic drugs have been widely used in the treatment of cancer disease for about 70 years and, even with the development of new therapies, they are still prescribed by oncologists, alone or in combination with other antineoplastic agents. All chemotherapies are able to provoke hypersensitivity reactions, even with different incidences, depending on the different class of these drugs, and these reactions are the third leading cause of fatal drug-induced anaphylaxis in the United States. In Europe deaths related to chemotherapy have also been reported. In particular, most reactions are provoked by platinum compounds, taxanes, epipodophyllotoxins and asparaginase. However, currently there are different points of view about the best procedures for the diagnosis, treatment and prevention of these reactions. Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology organized a task force to provide data and recommendations regarding the allergological work up in this field of drug hypersensitivity reactions. The aims of this position paper were to provide consensus on the investigation of HSRs to chemotherapeutic drugs and to give practical suggestions for clinicians that treat these patients, such as oncologists, allergologists and internists. Key sections cover: risk factors, pathogenesis, symptoms, role of skin tests, in vitro tests, indications and contraindications of drug provocation tests and desensitization of neoplastic patients with allergic reactions to chemotherapeutic drugs. Statements, recommendations and unmet needs were discussed and proposed at the end of each section.

Skin testing and drug challenge in the evaluation of drug hypersensitivity reactions

2021 ◽  
Vol 42 (1) ◽  
pp. 16-21 ◽  
Author(s):  
Anna R. Wolfson ◽  
Aleena Banerji
Keyword(s):  
Negative Impact ◽  
Skin Testing ◽  
Drug Hypersensitivity ◽  
Clinical History ◽  
Hypersensitivity Reactions ◽  
Causative Drug ◽  
Care Assessment ◽  
Drug Hypersensitivity Reactions ◽  
Drug Challenge ◽  
Drug Challenges

Immediate hypersensitivity to drugs is characterized by symptoms such as hives, swelling, and wheezing. To prevent a negative impact on care, assessment by an allergist is important. Evaluation requires a clear clinical history, but it is often lacking or vague, which makes a diagnosis difficult. Allergists instead can use skin testing and drug challenge to evaluate drug hypersensitivity reactions, which help the patient and provider understand the causative drug(s) and, more importantly, enables the use of the exonerated drug(s). Although penicillin skin testing is standardized, well described, and widely used, skin testing for most other drugs requires the use of a nonirritating skin testing concentration that can have a low negative predictive value. Drug challenges are the criterion standard for confirming tolerance. The allergist must obtain an in-depth clinical history and then follow with skin testing and/or drug challenges when indicated to determine which drugs can be de-labelled and which should be avoided. In this review, we focused on the evaluation of drug hypersensitivity reactions to antibiotics, perioperative agents, biologics, and chemotherapeutics.

Sign in / Sign up

Export Citation Format

Share Document